Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has reported very good numbers in Q2 2022. Those numbers include revenues of $4.8 million, up 80% over Q2-21. Saviuk telling Proactive the company saw gross margins of $1.7 million, up 134% over Q2-21. Saviuk says the numbers are being led by their 3 lead brands, Redesca, Enerzair and Atectura. In fact, Redesca has captured a 54% share of the Canadian low molecular weight heparin biosimilar market.
About this content
About Steve Darling
Steve Darling is an award winning broadcaster who has spent the past 20 years as one of the most recognizable faces in British Columbia, reporting and anchoring at BCTV and Global Television. He spent 15 years as the co-host of the number one morning new program in the province. Steve is a tireless worker for charity hosting some 50 events a year. He is an ambassador for the Canucks Autism Network and hosts numerous events with BC Children’s Hospital and the Child Development foundation of... Read more
About the publisher
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.
Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.
We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.
The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.
Use of technology
Proactive has always been a forward looking and enthusiastic technology adopter.
Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.
Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.
No investment advice
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter. You understand...
In exchange for publishing services rendered by the Company on behalf of Valeo Pharma Inc. named herein, including the promotion by the Company of Valeo Pharma Inc. in any Content on the Site, the Company receives from said issuer annual cash compensation of typically up to $25,000.
FOR OUR FULL DISCLAIMER CLICK HEREValeo Pharma sees 80% increase in revenue year over year as company reports Q2 financials
Published: 10:54 15 Jun 2022 EDT